(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Superstar Couples That Motivate Relationship Objectives - 2How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 3Best Pizza Beating: What's Your #1?
- 4I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- 5Which Breakfast Enraptures Your Taste Buds? Vote
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Top 15 Web-based Entertainment Stages for Individual Marking
- Blood pressure drug recalled for possible cross-contamination
- Improving as a Cook: Culinary Experiences in the Kitchen
- Polar bears are rewiring their own genetics to survive a warming climate
- New hybrid mpox strain discovered in UK after US reports local spread
- Figure out How to Reveal Stowed away Open Record Rewards
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
